

# Lawrence Berkeley National Laboratory

## Lawrence Berkeley National Laboratory

### **Title**

The MAPKERK-1,2 pathway integrates distinct and antagonistic signals from TGF alpha and FGF7 in morphogenesis of mouse mammary epithelium

### **Permalink**

<https://escholarship.org/uc/item/7075z967>

### **Author**

Fata, Jimmie E

### **Publication Date**

2007-03-16

### **DOI**

10.1016/j.ydbio.2007.03.013

Peer reviewed

**The MAPK<sup>ERK-1,2</sup> pathway integrates distinct and antagonistic signals from TGF $\alpha$  and FGF7 in morphogenesis of mouse mammary epithelium**

Jimmie E. Fata<sup>a\*</sup>, Hidetoshi Mori<sup>a</sup>, Andrew J. Ewald<sup>b</sup>, Hui Zhang<sup>a</sup>, Evelyn Yao<sup>a</sup>,  
Zena Werb<sup>b</sup>, Mina J. Bissell<sup>a\*</sup>

<sup>a</sup> Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA

<sup>b</sup> Department of Anatomy, University of California, San Francisco, CA 94143, USA

\*Corresponding Authors:

Jimmie Fata

Life Science Division, Lawrence Berkeley National Laboratory

One Cyclotron Road, Berkeley, CA 94720, USA

e-mail: jefata@lbl.gov

Mina Bissell

Life Science Division, Lawrence Berkeley National Laboratory

One Cyclotron Road, MS 977R225A, Berkeley, CA 94720, USA

e-mail: mjbissell@lbl.gov

Tel: +1 510 486 4365

Fax: +1 510 486 5586

LBNL/DOE funding & contract number: DE-AC02-05CH11231

## Abstract

Transforming growth factor- $\alpha$  (TGF $\alpha$ ) and fibroblast growth factor-7 (FGF7) exhibit distinct expression patterns in the mammary gland. Both factors signal through mitogen-activated kinase/extracellular regulated kinase-1,2 (MAPK<sup>ERK1,2</sup>); however, their unique and/or combined contributions to mammary morphogenesis have not been examined. In *ex vivo* mammary explants, we show that a sustained activation of MAPK<sup>ERK1,2</sup> for 1 h, induced by TGF $\alpha$ , was necessary and sufficient to initiate branching morphogenesis, whereas a transient activation (15 min) of MAPK<sup>ERK1,2</sup>, induced by FGF7, led to growth without branching. Unlike TGF $\alpha$ , FGF7 promoted sustained proliferation as well as ectopic localization of, and increase in, keratin-6 expressing cells. The response of the explants to FGF10 was similar to that to FGF7. Simultaneous stimulation by FGF7 and TGF $\alpha$  indicated that the FGF7-induced MAPK<sup>ERK1,2</sup> signaling and associated phenotypes were dominant: FGF7 may prevent branching by suppression of two necessary TGF $\alpha$ -induced morphogenetic effectors, matrix metalloproteinase-3 (MMP-3/stromelysin-1), and fibronectin. Our findings indicate that expression of morphogenetic effectors, proliferation, and cell-type decisions during mammary organoid morphogenesis are intimately dependent on the duration of activation of MAPK<sup>ERK1,2</sup> activation.

## Keywords

MAPK<sup>ERK1,2</sup>

Kinetics

Mammary

Branching

Morphogenesis

TGF $\alpha$

FGF7

## Introduction

Branch formation in the mammary gland results from an intricate interplay between cell intrinsic and extrinsic factors. These extracellular factors can be grouped broadly into, but not limited to, hormones, growth factors, proteases, and the extracellular matrix (ECM), each of which have been demonstrated to be required for normal mammary development ([Fata et al., 2004], [Hovey et al., 2002], [Parmar and Cunha, 2004], [Schedin et al., 2004] and Sternlicht, 2006 M.D. Sternlicht, Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis, *Breast Cancer Res.* **8** (2006), p. 201. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (0)[Sternlicht, 2006]).

Members of the epidermal and fibroblast growth factor receptor (EGFR, FGFR) families are required for normal mammary development ([Mailleux et al., 2002] and [Sternlicht, 2006]), and a number of growth factors have been shown to have functional roles including EGFR and FGFR ligands ([Luetteke et al., 1999], [Mailleux et al., 2002] and [Sternlicht et al., 2005]). A major unresolved question is how these signals are temporally integrated to

generate the diverse range of morphogenetic behaviours observed during mammary development and differentiation.

The mitogen-activated protein kinase (MAPK) pathway includes a three kinase cassette of Rous sarcoma associated factor (Raf), mitogen-activated protein/ERK kinase (MEK), and extracellular regulated kinase (ERK), producing a sequential activation pathway responsive to a diverse array of extracellular stimuli (Roux and Blenis, 2004). A fundamental question of signal transduction is how the canonical components of the MAPK pathway, Raf → MEK → ERK, integrate signals from multiple stimuli into distinct cellular outcomes ([Marshall, 1995] and [Schlessinger, 2004]). For instance, the rat pheochromocytoma PC12 cell line proliferates in response to EGF but differentiates in response to nerve growth factor (NGF), although both stimuli elicit activation of the Raf → MEK → ERK cassette ([Qui and Green, 1992] and [Traverse et al., 1992]). Efforts into resolving this question have focused on the duration of the signal through ERK-1 and ERK-2 (MAPK<sup>ERK1,2</sup>) as a key factor determining the fate of a single cell or groups of cells grown on tissue culture plastic. Intense MAPK<sup>ERK1,2</sup> phosphorylation is evident by whole-mount immunohistochemistry in the course of the development of certain organs during mouse embryogenesis, including the branchial arches, limbs, and lung buds (Corson et al., 2003). Prolonged activation of MAPK<sup>ERK1,2</sup>, in response to hepatocyte growth factor, is associated with immortalized kidney cells undergoing tubulogenesis in collagen type-1 gels ([Karihaloo et al., 2004] and [Maroun et al., 1999]). Signalling through the MAPK<sup>ERK1,2</sup> pathway is necessary for the development of branched organs such as the lung (Kling et al., 2002), kidney (Hida et al., 2002), and salivary gland (Kashimata et al., 2000), but whether the duration of MAPK<sup>ERK1,2</sup> phosphorylation is indeed a developmentally relevant regulator of organogenesis has not been addressed.

To examine the interplay between growth factor signals, MAPK<sup>ERK1,2</sup> activation, and mammary branching morphogenesis, we utilized an organotypic 3D mammary primary culture that models aspects of branching morphogenesis in vivo and is responsive to growth factors produced in the mammary gland. In this assay, the mammary epithelium is separated from most of the stroma but retains epithelial/myoepithelial spatial organization, allowing us a framework to evaluate the precise role of signalling modules in a controlled and reproducible environment. We show that individually as well as in combination, TGF $\alpha$  and FGF7 elicit distinct kinetics of MAPK<sup>ERK1,2</sup> activation that in turn predicts both cellular and morphogenetic outcomes

Materials and methods

### **Isolation of primary mammary organoids**

The 4th inguinal mammary glands were removed from 10 to 14 weeks old virgin Balb/c mice and minced with two parallel razor blades (approved by the Animal Welfare and Research Committee (AWRC) at Lawrence Berkeley Labs; animal protocol #0522). At this age the expansion of the ductal tree within the fat pad is complete and no terminal end buds exist. Minced tissue (4–8 glands) was gently shaken for 30 min at 37 °C in a 50-ml collagenase/trypsin mixture (0.2% trypsin, 0.2% collagenase type IV, 5% fetal calf serum,

5 µg/ml Insulin, 50 µg/ml gentamycin, in 50 ml of DMEM/F12). The collagenase solution was discarded after centrifugation at 1000 rpm and the pellet was re-suspended in 10 ml DMEM/F12. The suspension was pelleted again at 1000 rpm for 10 min, re-suspended in 4 ml of DMEM/F12 + 40 µl of DNase (2 U/µl), and incubated for 5 min at ambient temperature with occasional shaking. The DNase solution was removed after centrifugation at 1000 rpm for 10 min. The DNase solution was discarded and the epithelial pieces were separated from the single cells through differential centrifugation. The pellet was re-suspended in 10 ml of DMEM/F12 and pulsed to 1500 rpm. The supernatant was then removed and the pellet was re-suspended in 10 ml DMEM/F12. Differential centrifugation was performed at least 4 times. The final pellet was re-suspended in the desired amount of medium or Matrigel (Growth Factor Reduced Matrigel, BD Biosciences, San Jose, CA).

### **Morphogenesis assay**

Morphogenesis assays were performed in 96 well culture plates. The culture had two layers, an underlay of 50 µl of Matrigel (Growth Factor Reduced Matrigel, BD Biosciences) and an overlying layer of organoids suspended in Matrigel. The underlay was allowed to set for 30 min at 37 °C, and then a 50-µl suspension of organoids in Matrigel (~100–200 organoids/100 µl of Matrigel) was added to the well followed by an incubation of 30 min at 37 °C. All wells were then treated with 150 µl of basal media (DMEF/F12 with 1% insulin, transferrin, selenium, and 1% penicillin/streptomycin) for 24 h. After 24 h the basal media was replenished (untreated samples) or growth factors TGF $\alpha$  (9 nM; Sigma, Saint Louis, MO), FGF7 (9 nM; Sigma, Saint Louis, MO), or FGF10 (9 nM; Biosource, Camarillo, CA) were added to basal media individually or in combinations. Every other day all samples were replenished with basal media alone. To determine the morphogenic response we counted all organoids within each well (~100–200 organoids/well) having 3 or more branches and divided this number by the total number of organoids per well (Simian et al., 2001). For inhibition of MAPK<sup>ERK1,2</sup> signaling, PD98059 (Calbiochem, San Diego, CA) was added to growth factor-supplemented medium at a concentration of 40 µM. Inhibition of MMP-3 was accomplished with 30 µM of an MMP-3-specific peptide-based inhibitor containing the sequence Ac-Arg-Cys-Gly-Val-Pro-Asp-NH<sub>2</sub> (Calbiochem). The broad based metalloproteinase inhibitor, GM6001, was added to media at 40 µM. Inhibition of fibronectin adhesion was accomplished with blocking antibodies against  $\alpha$ 5 $\beta$ 1-integrin (Chemicon, Temecula, CA) at a concentration of 2 µg/ml.

### **RT-PCR**

Total RNA was isolated with QIAGEN RNeasy Mini Kit (Valencia, CA). For cDNA synthesis, 20 ng of total cellular RNA was used to synthesize cDNA using SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA). MMP-3 was amplified with GTTCCTGATGTTGGTGGCTT and AGCCTTGGCTGAGTGGTAGA primers. Primers that detect fibronectin were TACCAAGGTCAATCCACACCCC and CAGATGGCAAAGAAAGCAGAGG. As a control for total RNA, RT-PCR for GAPDH was performed with primers TGAAGGTCGGTGTGAACGGATTTGGC and CATGTAGGCCATGAGGTCCACCAC.

The amplified fragments were resolved on 1% agarose gels and products were detected with a FluorChem 8900 analysis system (Alpha Innotech, San Leandro, CA). Real-time PCR was performed using LightCycler System (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's instructions. Fast Start DNA Master SYBR Green I (Roche Diagnostics, Indianapolis, IN) was used for PCR reaction. PCR data were analyzed with LightCycler Software ver.3 (Roche Diagnostics, Indianapolis, IN). Relative signals between fibronectin or MMP3 and 18s rRNA were quantified.

### **Protein isolation**

For protein isolation, media were removed from the well, and Matrigel+organoids were washed once with cold 1× PBS containing NaF (1 mM) and Na<sub>3</sub>VO<sub>4</sub> (1.25 mM). Matrigel and organoids were then treated with a 3D lysis solution consisting of 90% NP40 lysis mix (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 150 mM NaCl, 0.5% NP40) plus 10% 10× SDS loading buffer (83.3 μl 12 M acetate [70% glacial acetic acid (17.4 M) and 30% water], 3.67 ml water, 1.25 μl 2-mercaptoethanol, 0.01 g bromophenol blue, 5.0 ml glycerol, 1 g SDS). Samples were pipetted up and down and stored at -20 °C. The 3D lysis solution was heated to 65 °C just prior to using.

### **Immuno-detection of MAPK<sup>ERK1,2</sup> phosphorylation**

For immunoblot analysis, protein samples were heated at 65 °C for 5 min then placed on ice for 3–5 min. Samples were centrifuged at 13000 rpm for 5 min and the soluble portion was resolved on a pre-cast 10% Tris-glycine polyacrylamide gel (InVitrogen, Carlsbad, CA) using the NOVEX system (InVitrogen, Carlsbad, CA). Resolved proteins were transferred to Hybond nitrocellulose (Amersham, Piscataway, NJ) followed by blocking in 1× TBS, 0.1% Tween-20 with 5% w/v non-fat dry milk for 1 h at ambient temperature. Membranes were incubated overnight at 4 °C in 5% BSA, 1× TBS, 0.1% Tween-20 containing rabbit anti-human polyclonal antibodies that recognize either phosphorylated MAPK<sup>ERK1,2</sup> (Thr202/Tyr204, #9101, Cell Signaling Tech., Beverly, MA), phosphorylated MEK1 (Ser 98, #9128, Cell Signaling Tech., Beverly, MA), total MAPK<sup>ERK1,2</sup> (#9102, Cell Signaling Tech., Beverly, MA), or beta-Actin (#4967, Cell Signaling Tech., Beverly, MA). In some cases, determination of total MAPK was performed on separate membranes using identical samples. Primary antibodies were detected with the Pierce SuperSignal detection kit (Rockford, IL) and signal was captured with the FluorChem 8900 analysis system (Alpha Innotech, San Leandro, CA).

### **Immunocytochemical detection of Ki67, keratins, and receptors**

For detection of Ki67, keratin-8 (K8), keratin-14 (K14), and keratin-6 (K6), a mixture of 18% sucrose in PBS (15 min at ambient temperature) followed by 30% sucrose (15 min at ambient temperature) was applied to organoids in Matrigel to maintain organoid structure. After sucrose treatment, organoids in Matrigel were gently pipetted up and down and then smeared onto a glass slide. Smeared organoids were allowed to dry at ambient temperature for 2 h and then fixed in methanol: acetone (1:1 v/v) at -20 °C for 10 min. After fixation, slides were air-dried at ambient temperature for 2 h followed by blocking in 10% sheep

serum in PBS for 1 h at ambient temperature. The primary antibodies, rabbit polyclonal anti-human Ki67 (Ki67p, Novocastra, UK), rat monoclonal antimouse K8 (Troma-1, Iowa DSHB, Iowa City), mouse monoclonal anti-human K14 (clone #LL002, Novocastra, UK), rabbit polyclonal anti-mouse-K6 (PRB-169P, Covance Research Products, Berkeley), goat polyclonal anti-human FGFR2 (Bek N-20, Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit polyclonal anti-human EGFR (#2232, Cell Signaling Tech., Beverly, MA) were incubated in blocking buffer overnight at 4 °C, followed by 3×15 min washes in 0.5% Triton-X in PBS. For detection of primary antibodies, appropriate fluorophore-labeled secondary antibodies were used and images were captured using confocal microscopy. The generation of confocal stack montages and generation of threshold images for calculating double positive keratin cells were accomplished with ImageJ (NIH).

### **Live–dead cell detection**

To determine the ratio of live to dead cells, we used Molecular Probes (Carlsbad, CA) LIVE/DEAD Viability/Cytotoxicity Kit, which provides a twocolor discrimination of live and dead cell populations. For live cells a membrane permeant calcein AM, which is cleaved by intracellular esterases in live cells to yield cytoplasmic green fluorescence, was added to the assay. Dead cells, which have a compromised plasma membrane, were stained with the membrane impermeant nucleic acid dye, ethidium homodimer-1 yielding a red fluorescence. Both labels were incubated for 30 min at 37 °C and then visualized by fluorescent microscopy after excitation.

### **Real-time microscopy**

Time-lapse movies were collected on a ZeissAxiovert S-100 microscope using a 10× A-Plan objective lens and a Cohu high performance CCD camera. The light exposure was regulated by a Ludl shutter and controller, which also controlled the Ludl x–y–z motorized stage. Temperature was held at 37 °C and carbon dioxide at 5% using a CTI Controller 3700 and Temperature Control 37.2 combination. Images were acquired at each of 48 positions every 15 min using a custom macro implemented in OpenLab 4.0.2. (Improvisation Inc., Lexington, Mass).

## **Results**

### **TGF $\alpha$ induces branching morphogenesis in primary mammary organoids cultured within a 3D ECM gel**

To examine mammary morphogenesis, we developed an organotypic 3D culture system consisting of primary mammary organoids (which contain both the epithelium and the myoepithelium, but not the adipogenic stroma) within a 3D laminin-rich extracellular matrix (3D lrECM; Matrigel). The basal medium is chemically defined (see Materials and methods) and was designed to support cell survival, but not induce branching morphogenesis (Fig. 1A). TGF $\alpha$  in concentrations between 1 nM and 100 nM were added to the organoids, and all doses were sufficient to induce branching. We chose a dose of 9 nM for TGF $\alpha$  for all experiments described because it was shown previously by us that 9 nM of

EGF induces branching morphogenesis of mammary organoids in collagen type I gels (Simian et al., 2001). Branching occurred with similar frequency and pattern whether we added TGF $\alpha$  to the medium only once in the beginning of the assay or every other day (data not shown). Time-lapse microscopy showed that branch formation in TGF $\alpha$ -treated organoids was evident within the first 48 h, with the majority of bud initiation and extension observed between 48 and 72 h (Fig. 1A and Supplemental Movie 1). Branch extension, however, was limited, often resulting in a short stalk. Untreated organoids did not initiate new branches but reorganized to form acinar-like structures (Fig. 1A and Supplemental Movie 2).

### **FGF7 suppresses TGF $\alpha$ -induced morphogenesis**

The mammary gland undergoes a diverse range of morphogenetic transformations during puberty, pregnancy, lactation, and involution. Which growth factors act in what combination to bring about this diversity is still poorly understood. We chose to examine the known mammary mitogens, TGF $\alpha$  and FGF7, since the two factors exhibit both distinct and overlapping temporal and spatial regulation. TGF $\alpha$  is expressed primarily in mammary epithelial cells and is elevated during branching morphogenesis and pregnancy-induced alveologenesis (Liscia et al., 1990). FGF7 is expressed primarily in the stroma, is high prior to the onset of extensive branching and declines thereafter, becoming minimal during alveologenesis (Mailleux et al., 2002; Pedchenko and Imagawa, 2000). We asked whether the actions of these two factors through MAPK<sup>ERK1,2</sup> were in fact redundant for morphogenesis or whether the response of organoids to FGF7 was distinct from that of TGF $\alpha$ . Whereas TGF $\alpha$  induced branching, FGF7 induced growth (Fig. 1B and Supplemental Movie 3). Morphometric analysis showed that approximately 80% of organoids produced branches within 5 days in response to TGF $\alpha$ ; the rest resembled the untreated controls (Fig. 1C). Surprisingly, when FGF7 was added together with TGF $\alpha$ , it suppressed TGF $\alpha$ -induced branching in a dose-dependent fashion (Figs. 1B and C). A ratio of 4:1 (FGF7:TGF $\alpha$ ) led to an approximately 80% inhibition of morphogenesis in comparison to TGF $\alpha$  alone (Fig. 1C). Time-lapse video microscopy indicated that unlike TGF $\alpha$  alone, FGF7+TGF $\alpha$  induced extensive lumen expansion, and those organoids that did branch were aberrant with morphologies similar to FGF7 alone (Figs. 1B and C and Supplemental Movie 4), indicating that the FGF7 phenotype was dominant over TGF $\alpha$ -induced branching.

### **TGF $\alpha$ and FGF7 induce distinct MAPK<sup>ERK1,2</sup> phosphorylation Kinetics**

TGF $\alpha$  and FGF7 signal through different receptors, yet each ligand is a potent activator of MAPK<sup>ERK1,2</sup>. To understand how TGF $\alpha$  and FGF7 lead to such dramatically different morphogenetic outcomes despite using the same signalling pathway, we assayed the phosphorylation kinetics of MEK1 and MAPK<sup>ERK1,2</sup> by immunoblotting protein lysates that were isolated at discrete time points after growth factor stimulation using anti-phospho-MEK/MAPK<sup>ERK1,2</sup> antibodies. TGF $\alpha$  stimulation induced rapid phosphorylation of both MEK1 (Fig. 2A) and MAPK<sup>ERK1,2</sup> (Fig. 2B), which peaked as early as 15 min and was sustained for up to 1 h. Between 1 and 2 h after TGF $\alpha$  stimulation, phospho-MEK1 and phospho-MAPK<sup>ERK1,2</sup> levels decreased but remained well above the basal levels for at least



24 h (Figs. 2A, B and data not shown). FGF7 stimulation of organoids also led to induction of both MEK1 and MAPK<sup>ERK1,2</sup> phosphorylation, but in contrast to TGF $\alpha$ , high levels of these kinases were evident for only 15 min (Figs. 2A, B).

Since we already knew that simultaneous addition of FGF7 and TGF $\alpha$  leads to a morphogenetic outcome similar to that of FGF7 alone, it was not surprising that the phospho-MAPK<sup>ERK1,2</sup> duration also resembled the FGF7-like pattern (Fig. 2B). outcome and (b) whether the initial signal activated by TGF $\alpha$  could be sufficient to elicit the entire 5-day morphogenetic program. Pre-treatment of organoids with PD98059 (20  $\mu$ M), an inhibitor of MAPK<sup>ERK1,2</sup> phosphorylation for 1 h prior to TGF $\alpha$  stimulation inhibited MAPK<sup>ERK1,2</sup> activation (Fig. 3A), and abolished branching morphogenesis (Fig. 3Bb and Supplemental Movie 5; compare to TGF $\alpha$  treatment alone (Fig. 3Ba) and Supplemental Movie 1). Similar results were seen when PD98059 (40  $\mu$ M) was added simultaneously with TGF $\alpha$  (Fig. 3Bc). However, addition of PD98059 at 1, 4, 24, 48, or 72 h, post-TGF $\alpha$  stimulation, yielded a partial decrease in branching morphogenesis (Fig. 3Bb; and data not shown), indicating that the initial 1 h phosphorylation of MAPK<sup>ERK1,2</sup> was necessary and sufficient for transducing the MAPK<sup>ERK1,2</sup>-dependent component of the TGF $\alpha$  signal for branching. PD98059 added 1 h after TGF $\alpha$  stimulation was effective in inhibiting branches in 50% of organoids vs. 10% when it was added 4 h after TGF $\alpha$  stimulation (Fig. 3Be; compare to TGF $\alpha$  stimulation alone). The incomplete response to 1 h of TGF $\alpha$  activation suggests that additional and as yet undetermined factors may be necessary to allow the organoids to fully respond to TGF $\alpha$ . However, the inability of PD98059 to Quantification of the kinetics of phospho-MAPK<sup>ERK1,2</sup> levels revealed a significant difference in the first 3 h between organoids stimulated with TGF $\alpha$  compared to organoids stimulated with FGF7 alone or with both FGF7 and TGF $\alpha$  (Fig. 2C; \*p<0.05).

### **A brief window of TGF $\alpha$ -induced MAPK<sup>ERK1,2</sup> activation sustains a prolonged morphogenetic program**

Given the results obtained above, we asked (a) whether the MAPK pathway was responsible for the morphogenetic outcome and (b) whether the initial signal activated by TGF $\alpha$  could be sufficient to elicit the entire 5-day morphogenetic program. Pre-treatment of organoids with PD98059 (20  $\mu$ M), an inhibitor of MAPK<sup>ERK1,2</sup> phosphorylation for 1 h prior to TGF $\alpha$  stimulation inhibited MAPK<sup>ERK1,2</sup> activation (Fig. 3A), and abolished branching morphogenesis (Fig. 3Bb and Supplemental Movie 5; compare to TGF $\alpha$  treatment alone (Fig. 3Ba) and Supplemental Movie 1). Similar results were seen when PD98059 (40  $\mu$ M) was added simultaneously with TGF $\alpha$  (Fig. 3Bc). However, addition of PD98059 at 1, 4, 24, 48, or 72 h, post-TGF $\alpha$  stimulation, yielded a partial decrease in branching morphogenesis (Fig. 3Bb; and data not shown), indicating that the initial 1 h phosphorylation of MAPK<sup>ERK1,2</sup> was necessary and sufficient for transducing the MAPK<sup>ERK1,2</sup>-dependent component of the TGF $\alpha$  signal for branching. PD98059 added 1 h after TGF $\alpha$  stimulation was effective in inhibiting branches in 50% of organoids vs. 10% when it was added 4 h after TGF $\alpha$  stimulation (Fig. 3Be; compare to TGF $\alpha$  stimulation alone). The incomplete response to 1 h of TGF $\alpha$  activation suggests that additional and as yet undetermined factors may be necessary to allow the organoids to fully respond to TGF $\alpha$ . However, the inability of PD98059 to significantly inhibit branching after 4 h

indicate that the majority of molecules necessary for branching are induced before the 4-h period. It should also be noted that it is not possible to tightly control ERK activation kinetics with PD98059 since the inhibitor functions by inactivating MEK that is not activated and does not affect activated MEK (Ballif and Blenis, 2001).

### **MMP-3 and fibronectin mediate TGF $\alpha$ -induced mammary morphogenesis**

To investigate MAPK<sup>ERK1,2</sup>-dependent downstream effectors of TGF $\alpha$ -induced morphogenesis, we screened candidate genes suspected of being involved in branching using quantitative RT-PCR on samples isolated after TGF $\alpha$  stimulation with or without PD98059. In a screen of a panel of a number of factors reported to be necessary for branching which included matrix metalloproteinase-3 (MMP-3), MMP-9, MMP-14, tissue inhibitor of metalloproteinase-1 (Timp-1), urokinase plasminogen activator (uPA), epimorphin (EPM), and Twist, only MMP-3 and fibronectin registered positive as being both induced by TGF $\alpha$  and dependent on MAPK<sup>ERK1,2</sup> activation (Fig. 4A, and data not shown). In the absence of TGF $\alpha$ , MMP-3 and fibronectin mRNA expression was relatively low (Fig. 4A; the level of MMP-3/18s was  $0.23 \pm 0.2$  and that of fibronectin/18s was  $0.25 \pm 0.4$ —data are presented as mean ratio of each mRNA/18s rRNA  $\pm$  standard deviation as determined by quantitative real-time PCR). After TGF $\alpha$  stimulation, MMP3 and fibronectin mRNA displayed a 9-fold induction (Fig. 4A; MMP-3/18s,  $2.18 \pm 0.2$ ; fibronectin/18s,  $3.37 \pm 0.9$ ). Up-regulation of both MMP-3 and fibronectin by TGF $\alpha$  was suppressed significantly when PD98059 was added to the cultures (Fig. 4A;  $0.70 \pm 0.30$  MMP-3/18s and  $0.86 \pm 0.3$  fibronectin/18s). Importantly, FGF7 added alone failed to induce MMP-3 and fibronectin (data not shown), and when added with TGF $\alpha$ , it significantly suppressed the TGF $\alpha$ -induced up-regulation of fibronectin ( $0.56 \pm 0.03$  vs.  $2.18 \pm 0.2$  fibronectin/18s; Fig. 4B). Interestingly, TGF $\alpha$ -induced MMP-3 up-regulation was inhibited by only 50% ( $1.48 \pm 0.89$  vs.  $3.37 \pm 0.9$  MMP-3/18s;  $p=0.08$ ) in the presence of FGF7.

To test whether these candidate genes were necessary for TGF $\alpha$ -induced morphogenesis, we inhibited MMP-3 by a relatively selective peptide-based inhibitor (MMP-3 Inhibitor I). Morphogenesis was suppressed by about ~50%, often resulting in cyst-like structures containing a few stunted branches (Fig. 4C). However, a broad-spectrum inhibitor against all MMPs (GM6001) completely abolished branching and led to either small, underdeveloped acini (similar to Fig. 3Bb) or large, cyst-like structures as seen also with MMP-3 Inhibitor 1 (Fig. 4C).

Fibronectin inhibition was achieved by preventing its binding to its major receptor,  $\alpha 5 \beta 1$  integrin, using inhibitory antibodies. Morphogenesis was completely suppressed in approximately 40% of the organoids compared to the control antibodies which did not suppress (Fig. 4D). Those structures that did form in the presence of the inhibitory antibody had abnormal and often thick, underdeveloped branches (Fig. 4D). Thus, while other factors may be required, it is clear that both these candidate genes are necessary for TGF $\alpha$  induction of branching.

## **MAPK<sup>ERK1,2</sup> regulates organoid proliferation and apoptosis**

It has been argued that differentiation and growth are often incompatible in morphogenesis. To additionally explore the underlying reasons for the differences in response, we explored whether TGF $\alpha$  and FGF7 elicited different growth responses from the organoids. At day 2, organoids treated with TGF $\alpha$ , FGF7, or a combination of the two, had significantly higher Ki67-positive cells than untreated organoids (Figs. 5A, C). The TGF $\alpha$ -induced proliferation was dependent on MAPK<sup>ERK1,2</sup> activation since it was completely suppressed in organoids pre-treated with PD98059 (Figs. 5A, C). By day 4, TGF $\alpha$ -treated organoids stopped growing as shown by the absence of Ki67-positive cells (Fig. 5A) whereas organoids treated with FGF7 or FGF7 plus TGF $\alpha$  continued to proliferate, albeit to a lesser extent than seen on day 2 (Figs. 5A, C). Thus, the difference in mode of action of the two growth factors is not due to differences in the initial growth phase but may result partially from continued proliferation in the presence of FGF7.

To complete the analysis, we measured cell death under these different conditions. A significant number of dead cells were evident at both day 2 and day 4 in untreated organoids or in TGF $\alpha$ -stimulated organoids when pre-treated with PD98059 (Figs. 5B, C). In contrast, none of the growth factor-treated organoids had appreciable dead cells either at days 2 or 4, and there were no significant differences between TGF $\alpha$ - and FGF7-treated organoids (Figs. 5B, C). Thus, the kinetics of proliferation, and not apoptosis, is an additional defining feature associated with the different morphogenetic response of the two growth factors.

## **TGF $\alpha$ and FGF7 retain myoepithelial–epithelial polarity**

We have shown that acinar polarity is crucial in determining the rate of apoptosis in response to a number of chemotherapeutic agents and also a significant feature distinguishing normal and malignant epithelial cells (Weaver et al., 2002). The absence of a difference in apoptosis raised the possibility that the juxtaposition of the myoepithelial/epithelial cells, which determines basal tissue polarity (Gudjonsson et al., 2002), may be different under the two conditions. We performed immunocytochemistry using antibodies against K14 and K8, which detect myoepithelial and luminal epithelial cells, respectively. Confocal microscopic analysis of K14 immunostaining after 1 day of culture revealed that untreated organoids maintained a basal layer of K14-positive myoepithelial cells possessing long cellular processes and an inner layer of K8-positive luminal epithelial cells (Fig. 6A). Myoepithelial cells were numerous and they did not completely encapsulate the organoids but instead appeared to be woven around the luminal epithelial cells (Fig. 6A). Thus, the luminal epithelium is likely to have extensive direct contact with the BM, an arrangement that is observed also in vivo (Emerman and Vogl, 1986).

Organoids that had undergone branching morphogenesis after TGF $\alpha$  treatment had a similar spatial arrangement; with K14 myoepithelial cells surrounding K8 epithelial cells (Fig 6B). Intriguingly, a large subset (17.5 $\pm$ 3%) of the cells coexpressed both K14 and K8 (yellow in merged images Fig. 6B; Supplemental Fig. 1) after TGF $\alpha$  treatment. These cells

were invariably located at the distal ends of branches and may represent a subset of progenitor luminal cells (Pechoux et al., 1999; Shackleton et al., 2006). In untreated organoids, very few cells co-expressed K8 and K14 ( $1.4 \pm 0.2\%$ ; Supplemental Fig. 1). An examination of FGF7-treated or FGF7-TGF $\alpha$  dual-treated organoids revealed a similar orientation of myoepithelium to epithelium as that seen in TGF $\alpha$ -treated organoids (Fig. 6C, and data not shown), but fewer K8/K14 double positive cells were evident in the FGF7-treated compared to TGF $\alpha$ -treated organoids (Supplemental Fig. 1). Under all conditions, all organoids examined retained their central lumina. The developing branches also all contained lumina (Fig. 6).

### **FGF7 induces MAPK<sup>ERK1,2</sup>-dependent increase in K6-positive cells**

K6-positive cells were previously shown to be localized to hyperproliferative areas in the mouse mammary gland and skin; this keratin has been considered a putative marker of stem/progenitor mouse mammary cells in some studies (Li et al., 2003; Welm et al., 2005). Since FGF7 induced sustained proliferation in the organoids, we asked whether it also induced higher numbers of K6-positive cells. Only a few K6-positive cells were evident in untreated and TGF $\alpha$ -treated organoids (Fig. 7A). When found, the K6-positive cells were rarely evident in the distal ends of branches and were found only at the base of branches (Figs. 7A, B). FGF7, alone or in combination with TGF $\alpha$ , induced a significant increase in the number of K6-positive cells compared to TGF $\alpha$ -treated organoids (Figs. 7A, B). Up-regulation of K6 expression occurred as early as 48 h after FGF7 stimulation (data not shown). The large numbers of K6-cells encapsulating the organoids were often found within the outer distal cell layers (Figs. 7A, B). We also noted that there were at least two populations of K6-positive cells in FGF7- or FGF7+TGF $\alpha$ -treated organoids: those that were K6+/K8+ and those that were basal K6+/K14+ (Fig. 7B; Supplemental Figs. 2 and 3).

The FGF7-dependent effects also were MAPK<sup>ERK1,2</sup>-dependent. Treatment with PD98059 prior to FGF7 or FGF7+TGF $\alpha$  stimulation inhibited both the increase in proliferation and the increase in the number of K6-positive cells in organoids stimulated with FGF7 (Fig. 7C; compare proliferation with 5C). As seen with TGF $\alpha$ -cultures, suppression of MAPK<sup>ERK1,2</sup> in FGF7-treated organoids also increased the number of dead cells close to the level of untreated controls (compare Fig. 7C with Fig. 5C).

Since FGF10 and FGF7 signal through a common isoform of FGFR2 referred to as FGFR2-iiiib, we reasoned that many of the FGF7-associated phenotypes would be elicited also by FGF10. As expected, FGF10 failed to induce branching morphogenesis, inhibited TGF $\alpha$ -induced branching morphogenesis in a dose-dependent fashion, and up-regulated keratin-6 expression (Supplemental Fig. 4).

### **Discussion**

Mammary branching morphogenesis requires exquisite time-dependent coordination of signaling between the ECM, hormones, and growth factors. It is not yet possible to do rapid time course and multifactorial analysis *in vivo*. Thus, despite intense study of the individual components, we know little about the precise signaling pathways, and the

kinetics and mode of interactions among the different morphogenetic effectors. We developed a physiologically relevant, laminin-rich 3D assay where organoids from a few mice provide ample replicates and time points for such analysis.

We show that two growth factors produced by the mammary gland, TGF $\alpha$  and FGF7, induce very different outcomes in mammary organoids. A 1-h treatment with TGF $\alpha$ , followed by inhibition of MAPK<sup>ERK1,2</sup>, was sufficient to induce a program of robust branching observed days later, whereas FGF7 treatment led to sustained growth and to formation of continuously growing cysts. We showed that whereas both factors signal through the MAPK<sup>ERK1,2</sup> pathway, TGF $\alpha$  stimulation leads to high levels of MEK1, MAPK<sup>ERK1,2</sup> phosphorylation for at least 1 h, while FGF7 induces a shorter duration (15 min) of phosphorylation. When the two factors are added together, the FGF7 MAPK<sup>ERK1,2</sup>-dependent phenotype dominates and suppresses TGF $\alpha$ -induced branching (see Supplemental Movies 1–5).

Our data build upon the seminal work that found MAPK<sup>ERK1,2</sup> kinetics could determine the fate of PC12 cells cultured on conventional 2D plastic (Qui and Green, 1992; Traverse et al., 1992). These investigators found that EGF induced a rapid and transient induction of MAPK<sup>ERK1,2</sup> leading to cellular proliferation, while NGF induced a rapid but more prolonged phosphorylation, which in turn led to cellular differentiation. Therefore, a transient induction of MAPK<sup>ERK1,2</sup>, in the one case with EGF added to PC12 cells and here with FGF7 added to mammary organoids, promotes proliferation. In contrast, a sustained activation of MAPK<sup>ERK1,2</sup> in PC12 with NGF promotes neuronal extension and in mammary organoids with TGF $\alpha$  leads to branching morphogenesis. The dominance of the FGF7-induced morphogenetic outcome in the mammary gland mediated through a transient activation of MAPK<sup>ERK1,2</sup> may be achieved through sustained activation of growth pathways.

We have published previously that amphiregulin is an important ligand for branching development of embryonic mammary tissue and that it signals through the stroma (Sternlicht et al., 2005). This ligand was also shown to be important for the branching morphogenesis that initiates at the onset of puberty in young female mice. However, it is not expressed in adult mammary gland tissue (Luetke et al., 1999, and our unpublished data), the very tissue we are using in our study. There is strong evidence that in adult mice, branching occurs both during the estrous cycle and during gestation and primarily involves secondary or tertiary branching (Fata et al., 2001; Robinson et al., 2000; Atwood et al., 2000). Therefore, growth factors other than amphiregulin must regulate this morphogenetic process. We suggest that TGF $\alpha$ , which is expressed in adult mammary gland (Liscia et al., 1990), is a good candidate factor inducing morphogenesis during this time.

Transgenic overexpression of TGF $\alpha$  in epithelial cells of the mouse mammary gland induces extensive hyperplasia and occasional carcinoma (Matsui et al., 1990), and endogenously produced or exogenously added TGF $\alpha$  inhibits expression of whey acidic protein (WAP) in primary mammary epithelial cells (Lin et al., 1995). Others have shown that expression of a dominant-negative EGFR in mammary epithelium inhibits ductal

morphogenesis (Xie et al., 1997). These three studies indicate that TGF $\alpha$  is capable of acting directly on epithelial EGFR. However, transplantation studies and EGFR-null mammary tissue showed that signaling through stromal EGFR is required for extensive ductal outgrowth (Wiesen et al., 1999). Our current data suggest that exogenously added TGF $\alpha$  in this model system can induce signaling to epithelial EGFR and may mimic the stromal signaling required in vivo. It should be noted, however, that the branching seen in our organoids is more robust and exuberant than the spatially restricted branching seen in vivo in the mammary gland of virgin animals. We believe this is because in the 3D assay, the exogenous TGF $\alpha$  ligand is available to all the epithelial cells and leads to a global stimulation of the MAPK<sup>ERK1,2</sup> signal whereas in vivo there are likely discrete gradients of initiating or inhibitory signals, such as stromal TGF $\beta$  (Daniel et al., 1996; Nelson et al., 2006).

A possible explanation for the ability of TGF $\alpha$  to induce branching is that this growth factor induces two known morphogens, MMP-3 (Simian et al., 2001) and fibronectin (Sakai et al., 2003), and that these two factors are expressed in response to a prolonged activation of MAPK<sup>ERK1,2</sup>. In other cell types in culture, mRNA expression of MMP-3 and fibronectin also was shown to be dependent on MAPK<sup>ERK1,2</sup> activation (Gaggioli et al., 2005; Park et al., 2004). Our previous and current data provide evidence that MMP-3 controls lateral branching in vivo (Wiseman et al., 2003) and is required for growth factor-induced mammary branching in type I collagen gels (Simian et al., 2001). Other MMPs may also be involved since complete inhibition of MMP activity with the broad based MMP inhibitor, GM6001, leads to a more drastic suppression of morphogenesis than inhibition of MMP-3 alone. Intriguingly, we found that inhibition of MMPs promotes continued lumen expansion. We had hypothesized that both down-regulation of MMP activity and apolar expression of the mammary morphogen, epimorphin, may play a role in formation of acinar lumen during late pregnancy and lactation (Hirai et al., 1998; Hirai et al., 2001). The data presented here indicate that FGF7 inhibits induction of MMP3. Thus, it would be interesting to investigate whether fibronectin is inhibited when epimorphin leads to lumen formation.

Fibronectin is a key factor regulating branching in a number of organs including the alivary gland (Larsen et al., 2006; Sakai et al., 2003). Here we show that this ECM molecule also participates in branching in the mammary gland. Inhibition of the fibronectin receptor ( $\alpha 5\beta 1$ ) using blocking antibodies leads to altered morphogenesis where branch extensions are reduced and development verges on abnormal growth. The ability of FGF7 to suppress fibronectin expression may thus be an important reason for its ability to be dominant over TGF $\alpha$ 's ability to induce branching.

It is intriguing that both TGF $\alpha$  and FGF7 changed the profile of the keratin-expressing cells and stimulated two different progenitor cell populations. Whereas TGF $\alpha$  induced an increase in K8+/K14+ cells, FGF7 increased the number of K8+/K6+ and K14+/K6+-positive cells. The K8+/K14+ (similar to K19+/K14+) cell-type has been suggested to represent luminal progenitor cells (Gudjonsson et al., 2002; Shackleton et al., 2006). Interestingly, cells double positive for K8+/K14+ are the majority cell type in embryonic urogenital sinus epithelium and the developing prostatic epithelium and are considered

progenitor/stem cells within these tissues (Wang et al., 2001). In mammary epithelium, K8<sup>-</sup>/K14<sup>+</sup> cells, which represent the myoepithelial population, can be derived from the K8<sup>+</sup>/K14<sup>-</sup> luminal epithelium (Pechoux et al., 1999). The importance of myoepithelial cells in mammary gland biology and breast cancer has received recent attention (Adriance et al., 2005; Faraldo et al., 2005). Aside from myoepithelial cells being important for milk ejection, they have been shown to act also as natural tumor suppressors which can establish or maintain acini polarity (Gudjonsson et al., 2002). It may be reasonable to hypothesize that in the absence of functional myoepithelial cells, branching morphogenesis would likely not occur properly. Specific ablation of either myoepithelial function or myoepithelial cells as a whole could address this hypothesis and conditional gene targeting could be used, as it has previously, as an *in vivo* approach to better understand the many functions these cells appear to execute (Faraldo et al., 2005).

A previous study using our assay and organoids from embryonic (e18.5) mammary glands showed that FGF7 did in fact induce branching morphogenesis (Sternlicht et al., 2005). The explanation lies in the fact that at different stages of mammary gland development, the composition of the ligands and the receptors change, i.e. this is an age-dependent phenomenon. A comparison of organoids from these two different age groups (embryonic vs. 10–14 weeks old) in the same mouse background in the same experiment confirmed that the response of mammary epithelium to FGF7 in 3D cultures is dependent on the age of the donor mouse (unpublished results). In this report, we used organoids from adult (10–14 weeks old) mammary glands, and under these conditions, FGF7 not only fails to induce branching but also inhibits TGF $\alpha$ -induced morphogenesis pointing to the exquisite, stage- and time-dependent changes that occur in the mammary gland as it develops after birth. Indeed, expression of both mammary epithelial FGF7 receptor and stromal FGF7 has been shown to be developmentally regulated (Coleman-Krnacik and Rosen, 1994; Mailleux et al., 2002; Pedchenko and Imagawa, 2000), suggesting that the ratio of ligand to receptor may be one important reason for the altered morphogenetic outcome.

FGF7-dependent phenotypes were dependent on a transient induction of MAPK<sup>ERK1,2</sup> since both proliferation and expansion of K6-positive cells by FGF7 were inhibited completely by PD98059. K6<sup>+</sup> cells were shown to localize to hyperproliferative areas in Wnt-1 tumors and terminal end buds within the mouse mammary gland and were proposed also to represent a marker for stem/progenitor mouse mammary cells (Li et al., 2003; Welm et al., 2005). Recently, a sub-population of mammary epithelial cells having high levels of the stem cell marker Sca-1, and displaying properties of mammary stem/progenitor cells, were found to be primarily K6 positive (Deugnier et al., 2006). However, mammary glands examined from K6-embryonic knockout mice revealed that this keratin may not be necessary for ductal development, possibly arguing against K6 as a functional molecule for maintenance of the stem/progenitor cell population in the mammary gland (Grimm et al., 2006). The exact mechanism by which FGF7 induces K6 expression while TGF $\alpha$  does not remains to be elucidated. The difference between these two growth factors may lie in their ability to induce distinct transcription factors. For instance, in the development of the *Drosophila* air sac, which requires both FGF and EGF signaling, the ets domain transcription factor, Pointed (downstream of MAPK<sup>ERK1,2</sup> activation) is needed for

branchless/FGF-induced cell migration but dispensable for EGF-induced cell proliferation/survival (Cabernard and Affolter, 2005). Although the development of the *Drosophila* trachea is quite different from branching morphogenesis in the mouse mammary gland, the conserved signalling cascades have given insights into the mechanisms of how different growth factors elicit different morphogenetic responses within the same tissue.

FGF10 mimicked several of the phenotypes induced by FGF7, which is consistent with the report that these two growth factors signal through the common receptor FGFR2-iiiib. Both FGF10 and FGFR2-iiiib have been shown to be necessary for mammary placode/ductal development during embryogenesis (Mailleux et al., 2002). FGF7-null mice are at least capable of lactation (Guo et al., 1996), indicating that FGF7 may not be necessary for functional lobulo-alveolar morphogenesis. However, to our knowledge there has not been a complete analysis of the female mammary gland isolated from FGF7-null female mice—leaving it an open question as to whether this growth factor is or is not important for mammary branching morphogenesis *in vivo*.

We are currently investigating how FGF7 may antagonize TGF $\alpha$ -induced signalling and morphogenesis. This antagonism would prove difficult to study in the complex *in vivo* environment, which could possibly explain the absence of previous reports on this interesting finding. Our initial efforts have focussed on determining the localization of the receptors for TGF $\alpha$  and FGF7 (EGFR and FGFR2 respectively) in organoids. These efforts have identified an apparent spatial difference found within the myoepithelial compartment. Specifically, FGFR2 is abundant within myoepithelial cells while EGFR is restricted to a few myoepithelial cells/organoid (Supplemental Fig. 5). Within the luminal epithelial compartment, both EGFR and FGFR2 appear to be distributed homogeneously in all cells. Therefore, FGF7 may antagonize TGF $\alpha$ -induced signalling and morphogenesis directly in luminal cells (and the few myoepithelial cells that contain both EGFR and FGFR2) as well as indirectly by modulating those myoepithelial cells that lack EGFR. The latter process would involve a mechanism independent of regulating MAPK<sup>ERK1,2</sup> activation. Alterations in these two compartments would affect morphogen expression and cell–cell communication that together may override TGF $\alpha$ -induced morphogenesis. How FGF7 antagonizes TGF $\alpha$  activation of MAPK<sup>ERK1,2</sup> could involve mechanisms that include augmenting EGFR receptor turnover through FGF7-activation of the ubiquitin ligase Cbl (Schlessinger, 2004), increasing MAPK phosphatase activity, and/or inhibiting induction of RAPI which has been shown to sustain MAPK<sup>ERK1,2</sup> activation (York et al., 1998). Whereas we cannot be certain that the TGF $\alpha$ - and FGF7-associated phenotypes are solely dependent on MAPK<sup>ERK1,2</sup> activation, our data clearly indicate that distinct activation kinetics are associated with distinct phenotypes.

In summary, we find that phosphorylation of MAPK<sup>ERK1,2</sup> and duration of its activation are directly related to outcome in the organotypic 3D primary culture system we have developed to study mammary gland branching morphogenesis. We find that the interplay between the different growth factors, their spatial localization, and the duration of their activation as well as downstream effectors such as MMP-3 and fibronectin cooperate and choreograph whether mammary branches initiate and elongate. Finally, the interplay



between TGF $\alpha$  and FGF7 suggests that the mammary epithelium integrates multiple and simultaneously delivered growth factor signals in part, at the level of the duration of the MAPKERK1,2 signal. It will be informative to develop genetic mouse models where MAPKERK1,2 activation kinetics could be precisely controlled within the mammary gland to test whether or not the kinetics of MAPKERK1,2 activation is the sole determinant for the morphogenetic outcomes observed.

#### Acknowledgments

This work was supported by grants from the United States Department of Energy, Office of Biological and Environmental Research (DEAC0376SF00098) to MJB, the National Cancer Institute (CA57621) to ZW, and MJB and a grant (ES012801) to ZW jointly funded by the National Institute of Environmental Health Sciences and National Cancer Institute. JEF was supported, in part, by the California Breast Cancer Research Program (FB-0131) and by the Department of Defense Breast Cancer Research Program (DAMD17-03-1-0486). HM was supported by the Susan G. Komen Breast Cancer Foundation (02-1591). AJE was supported by NIH Grant number HL-007731 (NRSA Institutional Fellowship) and by the California Breast Cancer Research Program (11FB-0015). MJB is the recipient of both an Innovator award from the DOD Breast Cancer Program and a Distinguished Fellowship in Life Sciences from the OBER Office of the US DOE. The timelapse microscopy was done using equipment from the UCSF Comprehensive Cancer Center LCA Core. We also thank Andy Finch for assistance in developing time-lapse microscope automations in OpenLab.

## References

- Adriance, M.C., Inman, J.L., Petersen, O.W., Bissell, M.J., 2005. Myoepithelial cells: good fences make good neighbors. *Breast Cancer Res.* 7, 190–197.
- Atwood, C.S., Hovey, R.C., Glover, J.P., Chepko, G., Ginsburg, E., Robison, W.G., Vonderhaar, B.K., 2000. Progesterone induces side-branching of the ductal epithelium in the mammary glands of peripubertal mice. *J. Endocrinol.* 167, 39–52.
- Ballif, B.A., Blenis, J., 2001. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. *Cell Growth Differ.* 12, 397–408.
- Cabernard, C., Affolter, M., 2005. Distinct roles for two receptor tyrosine kinases in epithelial branching morphogenesis in *Drosophila*. *Dev. Cell* 9, 831–842.
- Coleman-Krnacik, S., Rosen, J.M., 1994. Differential temporal and spatial gene expression of fibroblast growth factor family members during mouse mammary gland development. *Mol. Endocrinol.* 8, 218–229.
- Corson, L.B., Yamanaka, Y., Lai, K.M., Rossant, J., 2003. Spatial and temporal patterns of ERK signaling during mouse embryogenesis. *Development* 130, 4527–4537.
- Daniel, C.W., Robinson, S., Silberstein, G.B., 1996. The role of TGF-beta in patterning and growth of the mammary ductal tree. *J. Mammary Gland Biol. Neoplasia* 1, 331–341.
- Deugnier, M.A., Faraldo, M.M., Teuliere, J., Thiery, J.P., Medina, D., Glukhova, M.A., 2006. Isolation of mouse mammary epithelial progenitor cells with basal characteristics from the Comma-Dbeta cell line. *Dev. Biol.* 293, 414–425.
- Emerman, J.T., Vogl, A.W., 1986. Cell size and shape changes in the myoepithelium of the mammary gland during differentiation. *Anat. Rec.* 216, 405–415.
- Faraldo, M.M., Teuliere, J., Deugnier, M.A., Taddei-De La Hossieraye, I., Thiery, J.P., Glukhova, M.A., 2005. Myoepithelial cells in the control of mammary development and tumorigenesis: data from genetically modified mice. *J. Mammary Gland Biol. Neoplasia* 10, 211–219.
- Fata, J.E., Chaudhary, V., Khokha, R., 2001. Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17betaestradiol during the estrous cycle. *Biol. Reprod.* 65, 680–688.

Fata, J.E., Werb, Z., Bissell, M.J., 2004. Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. *Breast Cancer Res.* 6, 1–11.

Gaggioli, C., Deckert, M., Robert, G., Abbe, P., Batoz, M., Ehrenguber, M.U., Ortonne, J.P., Ballotti, R., Tartare-Deckert, S., 2005. HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinasedependent signaling pathway and induction of Egr-1. *Oncogene* 24, 1423–1433.

Grimm, S.L., Bu, W., Longley, M.A., Roop, D.R., Li, Y., Rosen, J.M., 2006. Keratin 6 is not essential for mammary gland development. *Breast Cancer Res.* 8, R29.

Gudjonsson, T., Villadsen, R., Nielsen, H.L., Ronnov-Jessen, L., Bissell, M.J., Petersen, O.W., 2002. Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. *Genes Dev.* 16, 693–706.

Guo, L., Degenstein, L., Fuchs, E., 1996. Keratinocyte growth factor is required for hair development but not for wound healing. *Genes Dev.* 10, 165–175.

Hida, M., Omori, S., Awazu, M., 2002. ERK and p38 MAP kinase are required for rat renal development. *Kidney Int.* 61, 1252–1262.

Hirai, Y., Lochter, A., Galosy, S., Koshida, S., Niwa, S., Bissell, M.J., 1998. Epimorphin functions as a key morphoregulator for mammary epithelial cells. *J. Cell Biol.* 140, 159–169.

Hirai, Y., Radisky, D., Boudreau, R., Simian, M., Stevens, M.E., Oka, Y., Takebe, K., Niwa, S., Bissell, M.J., 2001. Epimorphin mediates mammary luminal morphogenesis through control of C/EBPbeta. *J. Cell Biol.* 153, 785–794.

Hovey, R.C., Trott, J.F., Vonderhaar, B.K., 2002. Establishing a framework for the functional mammary gland: from endocrinology to morphology. *J. Mammary Gland Biol. Neoplasia* 7, 17–38.

Karihaloo, A., Kale, S., Rosenblum, N.D., Cantley, L.G., 2004. Hepatocyte growth factor-mediated renal epithelial branching morphogenesis is regulated by glypican-4 expression. *Mol. Cell. Biol.* 24, 8745–8752.

Kashimata, M., Sayeed, S., Ka, A., Onetti-Muda, A., Sakagami, H., Faraggiana, T., Gresik, E.W., 2000. The ERK-1/2 signaling pathway is involved in the stimulation of branching morphogenesis of fetal mouse submandibular glands by EGF. *Dev. Biol.* 220, 183–196.

Kling, D.E., Lorenzo, H.K., Trbovich, A.M., Kinane, T.B., Donahoe, P.K., Schnitzer, J.J., 2002. MEK-1/2 inhibition reduces branching morphogenesis and causes mesenchymal cell apoptosis in fetal rat lungs. *Am. J. Physiol.: Lung Cell. Mol. Physiol.* 282, L370–L378.

Larsen, M., Wei, C., Yamada, K.M., 2006. Cell and fibronectin dynamics during branching morphogenesis. *J. Cell Sci.* 119, 3376–3384.

Li, Y., Welm, B., Podsypanina, K., Huang, S., Chamorro, M., Zhang, X., Rowlands, T., Egeblad, M., Cowin, P., Werb, Z., Tan, L.K., Rosen, J.M., Varmus, H.E., 2003. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. *Proc. Natl. Acad. Sci. U. S. A.* 100, 15853–15858.

Lin, C.Q., Dempsey, P.J., Coffey, R.J., Bissell, M.J., 1995. Extracellular matrix regulates whey acidic protein gene expression by suppression of TGF- $\alpha$  in mouse mammary epithelial cells: studies in culture and in transgenic mice. *J. Cell. Biol.* 129, 1115–1126.

Liscia, D.S., Merlo, G., Ciardiello, F., Kim, N., Smith, G.H., Callahan, R., Salomon, D.S., 1990. Transforming growth factor- $\alpha$  messenger RNA localization in the developing adult rat and human mammary gland by in situ hybridization. *Dev. Biol.* 140, 123–131.

Luetkeke, N.C., Qiu, T.H., Fenton, S.E., Troyer, K.L., Riedel, R.F., Chang, A., Lee, D.C., 1999. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. *Development* 126, 2739–2750.

Mailleux, A.A., Spencer-Dene, B., Dillon, C., Ndiaye, D., Savona-Baron, C., Itoh, N., Kato, S., Dickson, C., Thiery, J.P., Bellusci, S., 2002. Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. *Development* 129, 53–60.

Maroun, C.R., Holgado-Madruga, M., Royal, I., Naujokas, M.A., Fournier, T.M., Wong, A.J., Park, M., 1999. The Gab1 PH domain is required for localization of Gab1 at sites of cell–cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. *Mol. Cell. Biol.* 19, 1784–1799.

Marshall, C.J., 1995. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. *Cell* 80, 179–185.

Matsui, Y., Halter, S.A., Holt, J.T., Hogan, B.L., Coffey, R.J., 1990. Development of mammary hyperplasia and neoplasia in MMTV-TGF  $\alpha$  transgenic mice. *Cell* 61, 1147–1155.

Nelson, C.M., Dujin, M., Inman, J.L., Fletcher, D.A., Bissell, M.J., 2006. Tissue geometry determines sites of mammary branching morphogenesis in organotypic cultures. *Science* 314, 298–300.

Park, C.H., Lee, M.J., Ahn, J., Kim, S., Kim, H.H., Kim, K.H., Eun, H.C., Chung, J.H., 2004. Heat shock-induced matrix metalloproteinase (MMP)-1 and MMP-3 are mediated through ERK and JNK activation and via an autocrine interleukin-6 loop. *J. Invest. Dermatol.* 123, 1012–1019.

Parmar, H., Cunha, G.R., 2004. Epithelial–stromal interactions in the mouse and human mammary gland in vivo. *Endocr. Relat. Cancer* 11, 437–458.

Pechoux, C., Gudjonsson, T., Ronnov-Jessen, L., Bissell, M.J., Petersen, O.W., 1999. Human mammary luminal epithelial cells contain progenitors to myoepithelial cells. *Dev. Biol.* 206, 88–99.

Pedchenko, V.K., Imagawa, W., 2000. Pattern of expression of the KGF receptor and its ligands KGF and FGF-10 during postnatal mouse mammary gland development. *Mol. Reprod. Dev.* 56, 441–447.

Qui, M.S., Green, S.H., 1992. PC12 cell neuronal differentiation is associated with prolonged p21ras activity and consequent prolonged ERK activity. *Neuron* 9, 705–717.

Robinson, G.W., Hennighausen, L., Johnson, P.F., 2000. Side-branching in the mammary gland: the progesterone-Wnt connection. *Genes Dev.* 14, 889–894.

Roux, P.P., Blenis, J., 2004. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. *Microbiol. Mol. Biol. Rev.* 68, 320–344.

Sakai, T., Larsen, M., Yamada, K.M., 2003. Fibronectin requirement in branching morphogenesis. *Nature* 423, 876–881.

Schedin, P., Mitrenga, T., McDaniel, S., Kaeck, M., 2004. Mammary ECM composition and function are altered by reproductive state. *Mol. Carcinog.* 41, 207–220.

Schlessinger, J., 2004. Common and distinct elements in cellular signaling via EGF and FGF receptors. *Science* 306, 1506–1507.

Shackleton, M., Vaillant, F., Simpson, K.J., Stingl, J., Smyth, G.K., Asselin-Labat, M.L., Wu, L., Lindeman, G.J., Visvader, J.E., 2006. Generation of a functional mammary gland from a single stem cell. *Nature* 439, 84–88.

Simian, M., Hirai, Y., Navre, M., Werb, Z., Lochter, A., Bissell, M.J., 2001. The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. *Development* 128, 3117–3131.

Sternlicht, M.D., 2006. Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. *Breast Cancer Res.* 8, 201.

Sternlicht, M.D., Sunnarborg, S.W., Kouros-Mehr, H., Yu, Y., Lee, D.C., Werb, Z., 2005. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. *Development* 132, 3923–3933.

Traverse, S., Gomez, N., Paterson, H., Marshall, C., Cohen, P., 1992. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. *Biochem. J.* 288 (Pt. 2), 351–355.

Wang, Y., Hayward, S., Cao, M., Thayer, K., Cunha, G., 2001. Cell differentiation lineage in the prostate. *Differentiation* 68, 270–279.

Weaver, V.M., Lelievre, S., Lakins, J.N., Chrenek, M.A., Jones, J.C., Giancotti, F., Werb, Z., Bissell, M.J., 2002. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. *Cancer Cell* 2, 205–216.

Welm, A.L., Kim, S., Welm, B.E., Bishop, J.M., 2005. MET and MYC cooperate in mammary tumorigenesis. *Proc. Natl. Acad. Sci. U. S. A.* 102, 4324–4329.

Wiesen, J.F., Young, P., Werb, Z., Cunha, G.R., 1999. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. *Development* 126, 335–344.


Wiseman, B.S., Sternlicht, M.D., Lund, L.R., Alexander, C.M., Mott, J., Bissell, M.J., Soloway, P., Itohara, S., Werb, Z., 2003. Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. *J. Cell Biol.* 162, 1123–1133.

Xie, W., Paterson, A.J., Chin, E., Nabell, L.M., Kudlow, J.E., 1997. Targeted expression of a dominant negative epidermal growth factor receptor in the mammary gland of transgenic mice inhibits pubertal mammary duct development. *Mol. Endocrinol.* 11, 1766–1781.

York, R.D., Yao, H., Dillon, T., Ellig, C.L., Eckert, S.P., McCleskey, E.W., Stork, P.J., 1998. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. *Nature* 392, 622–626.

## Figures and Tables


FIGURE 1



Organoid response to TGF $\alpha$  and FGF7. (A) Untreated organoids fail to undergo major morphological changes, except a slight lumen expansion followed by compression from 48 to 60 h. In contrast, TGF $\alpha$  stimulation initiates bud formation (arrows) within 48 h, with the majority of morphogenesis occurring within the 48- to 72-h window. Images represent frames taken from movies (Supplemental Movies 1 and 2). (B, C) FGF7 fails to induce branching morphogenesis and suppresses TGF $\alpha$ -induced morphogenesis in a dose-dependent manner. Please see Supplemental Movies 3 and 4. (C) Morphometric analysis of branching morphogenesis. Scale bars represent 100  $\mu$ m. Data are represented as mean morphogenetic response  $\pm$  standard deviation (SD) and involve counting at least 100 organoids per condition per experiment.




FIGURE 2




FGF7 attenuates TGF $\alpha$ -induced MAPK<sup>ERK1,2</sup> activation. (A, B) Activation of high MEK1 (P-MEK1) and MAPK<sup>ERK1,2</sup> (P-p44, P-p42) levels are sustained for 1 h in organoids stimulated with TGF $\alpha$  compared to only 15 min in organoids stimulated with FGF7. Actin and total MAPK<sup>ERK1,2</sup> (p44, p42) are provided as loading controls. (B) FGF7 attenuates TGF $\alpha$  activation of MAPK<sup>ERK1,2</sup> when the growth factors are added simultaneously to the organoids. (C) Quantitative analysis of MAPK<sup>ERK1,2</sup> activation: MAPK<sup>ERK1,2</sup> activation in organoids treated with TGF $\alpha$  is significantly different than those treated with FGF7 \* [p<0.05], or those treated with FGF7 plus TGF $\alpha$  at 30, 60, and 180 min. Data are represented as the mean of phospho-MAPK<sup>ERK1,2</sup> levels/total MAPK<sup>ERK1,2</sup>  $\pm$  standard deviation (SD).

FIGURE 3




One hour of MAPK<sup>ERK1,2</sup> activation is necessary and sufficient for TGF $\alpha$ -induced morphogenesis. (A) TGF $\alpha$  induces a rapid increase in active MAPK<sup>ERK1,2</sup> activation. PD98059, the MEK inhibitor, suppresses TGF $\alpha$ -induced MAPK<sup>ERK1,2</sup> activation when added 1 h before TGF $\alpha$  stimulation. Active MAPK<sup>ERK1,2</sup> (P-p44/ P-p42) and total MAPK<sup>ERK1,2</sup> (p44/p42) were visualized on the same membrane in each condition. Membranes were transferred and developed simultaneously. (B) (a) TGF $\alpha$  alone. Pre-treatment with PD98059 for 1 h (b), or simultaneous addition with TGF $\alpha$  at time 0 h (c), completely inhibits morphogenesis (see the Supplemental Movie 5). Addition of PD98059 at 1 h (d) or 4 h (not shown) after TGF $\alpha$  treatment fails to inhibit morphogenesis completely. (C) Quantification of the percentage of organoids undergoing a morphogenic response similar to TGF $\alpha$ -treated samples (a=untreated, b=PD98059 pre-treatment followed by TGF $\alpha$ , c=TGF $\alpha$ +PD98059 added simultaneously, d=PD98059 added after 1 h of TGF $\alpha$  stimulation, e=PD98059 added after 4 h of TGF $\alpha$  stimulation). Scale bar equals 50  $\mu$ m. Data are represented as mean morphogenetic response $\pm$ SD and involve counting at least 100 organoids per condition per experiment.

FIGURE 4




Inhibition of MMP-3 activity and fibronectin adhesion alters TGF $\alpha$ -induced morphogenesis. (A) TGF $\alpha$  induces MAPK<sup>ERK1,2</sup>-dependent mRNA expression of MMP-3 and fibronectin. (B) FGF7 inhibits TGF $\alpha$ -induced expression of fibronectin mRNA levels (quantitative PCR). Data are represented as the mean ratio of fibronectin mRNA/18s $\pm$ SD. (C) A peptide-based inhibitor specific to MMP-3 (20  $\mu$ M) or the general metalloproteinase inhibitor, GM6001 (40  $\mu$ M) suppresses morphogenesis and often leads to formation of cyst-like structures. (D) Addition of a blocking antibody (2  $\mu$ g/ml) against the fibronectin receptor,  $\alpha 5\beta 1$  integrin alters morphogenesis, while a non-specific isotype IgG antibody (2  $\mu$ g/ml) has no effect. Quantification represents the percentage of structures undergoing morphogenesis under different conditions. Data are represented as mean morphogenetic response $\pm$ SD and involve counting at least 100 organoids per condition per experiment. Scale bars in panels C and D equal 200  $\mu$ m.

FIGURE 5




MAPK<sup>ERK1,2</sup> regulates organoid proliferation and apoptosis. (A) TGF $\alpha$ -induced proliferation (determined by Ki67 immunocytochemistry with DAPI counter stain for nuclei) is inhibited by PD98059 but augmented by FGF7. (B) Live cells are labeled with the vital dye Calcein AM (green) and dead cells are labeled with ethidium homodimer-1 (orange). Dead cells are prevalent in untreated and PD98059-treated organoids. (C) Organoids treated with FGF7 show continued proliferation on day 4. (C) TGF $\alpha$  plus PD98059-treated and control organoids analyzed at day 2 or day 4 have significantly higher apoptosis than those treated with TGF $\alpha$  or FGF7. \*Significantly different than all other conditions. Scale bars equal 50  $\mu$ m. Data are represented as mean percent Ki67 $\pm$ SD and mean percent apoptosis $\pm$ SD and involve counting at least 10 randomly selected organoids per condition per experiment.

FIGURE 6



Orientation of myoepithelial and epithelial cells is maintained in organoids undergoing morphogenesis. Indirect immunofluorescence for K14 (red; myoepithelium) and K8 (green; epithelium) in cultured organoids was captured by confocal microscopy. (A–C) Epithelial cells are the small tightly packed cuboidal cells. Myoepithelial cells are the larger cells displaying membrane extensions; they retain their basal orientation with respect to epithelial cells. (A) Untreated organoids, day 4. (B) TGF $\alpha$ -treated organoids, day 4. (C) FGF7-treated organoids, day 4. A montage of merged K8/K14 confocal stacks is represented in panels B and C and indicate that cells at the distal ends of branches in panel B are K8/K14 double positive (yellow signal). Lumina (\*) are evident in all structures treated with TGF $\alpha$  or FGF7. Scale bars in panel A equal 5  $\mu$ m (left panel) and 50  $\mu$ m (right panels). Scale bars in panels B and C equal 50  $\mu$ m.

FIGURE 7



FGF7 induces MAPK<sup>ERK1,2</sup>-dependent increase in K6-positive cells as well as organoid proliferation. (A) FGF7-induced K6-positive cells are evident on the outside of the organoid (day 4). (B) K6-positive cells in TGF $\alpha$ -treated organoids remain at the base of the branch, while K6-positive cells in FGF7-treated organoids are found both encapsulating and within the organoid. Some of these K6-positive cells are K8/K6 double positive (yellow). (C) FGF7-induced proliferation and increase in K6-positive cells is dependent on MAPK<sup>ERK1,2</sup> activation. Scale bar in panel A equals 25  $\mu$ m, in panel B equals 100  $\mu$ m, and in panel C equals 25  $\mu$ m.